Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J HAUKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578511283
CMS profile
297671
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$780.92

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $757.50 1
Education $23.42 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $757.50 1
Gilead Sciences, Inc. $11.92 1
Epizyme, Inc., $11.50 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J HAUKE

NPI 1578511283 · CMS profile ID 297671

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $780.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $757.5011/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788401241 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845873991 CMS
Epizyme, Inc., $11.5003/04/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832340057 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,629.00 9
PY2020 $7.49 1
PY2021 $780.92 3
PY2023 $16.02 1
PY2024 $225.23 10
PY2025 $31.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $609.30 2
PY2025 Principal investigator $1,167,738.55 292
PY2024 Principal investigator $1,299,594.58 212
PY2023 Principal investigator $2,735,258.21 252
PY2022 Recipient $4,157.00 1
PY2022 Principal investigator $1,567,591.67 137
PY2021 Principal investigator $2,060,900.77 213
PY2020 Recipient $705.81 1
PY2020 Principal investigator $1,867,000.72 289
PY2019 Principal investigator $1,377,455.65 354

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

252 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2023 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998415461
Principal investigator 1 Merck Sharp & Dohme LLC $12,884.98 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1042497519
Principal investigator 1 Merck Sharp & Dohme LLC $10,002.36 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1042497521
Principal investigator 1 Merck Sharp & Dohme LLC $2,149.80 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma No dispute reported 06/30/2026 1042497995
Principal investigator 1 Merck Sharp & Dohme LLC $12,406.40 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1042498429
Principal investigator 1 Merck Sharp & Dohme LLC $117,169.49 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1042498431
Principal investigator 1 Merck Sharp & Dohme LLC $14.43 12/31/2023 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase 2, Randomized, Double-Blind Study of Pembrolizumab MK-3475 plus Epacadostat INCB024360 Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1 No dispute reported 06/30/2026 1042498733
Principal investigator 1 Merck Sharp & Dohme LLC $6,252.29 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 1042513425
Principal investigator 1 Merck Sharp & Dohme LLC $10,843.51 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 1042520331
Principal investigator 1 Merck Sharp & Dohme LLC $16,353.74 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 1042521461
Principal investigator 1 Merck Sharp & Dohme LLC $6,503.72 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 1042536321
Principal investigator 1 Merck Sharp & Dohme LLC $21,932.52 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 1042542035
Principal investigator 1 Merck Sharp & Dohme LLC $272,139.42 12/31/2023 Non-covered Recipient Entity
Oncology Hematology West, PC DBA Nebraska Cancer Specialists
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 1042542741
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,131.70 12/21/2023 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1061177658
Principal investigator 1 Astellas Pharma Global Development $464.00 12/19/2023 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1022250223
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 12/14/2023 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049070025
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 12/14/2023 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049070035
Principal investigator 1 Merck Sharp & Dohme LLC $106,500.00 12/01/2023 Non-covered Recipient Entity
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042564967
Principal investigator 1 MACROGENICS, INC. $6,317.00 11/29/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1043830595
Principal investigator 1 BioNTech SE $250.00 11/28/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060315339
Principal investigator 1 Astellas Pharma Global Development $5,063.00 11/24/2023 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1022250245
Principal investigator 1 Janssen Research & Development, LLC $7,400.00 11/20/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156527
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,963.20 11/16/2023 Non-covered Recipient Entity
Bon Secours-st Francis Hospital
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1027480049
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,203.20 11/16/2023 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1027480999
Principal investigator 1 MACROGENICS, INC. $80.00 11/14/2023 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1043830357
Principal investigator 1 MACROGENICS, INC. $395.00 11/14/2023 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1043830427
Principal investigator 1 MACROGENICS, INC. $1,040.00 11/14/2023 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF TWO DOSE LEVELS OF VOBRAMITAMAB DUOCARMAZINE IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1043830441
Principal investigator 1 BioNTech SE $3,564.05 11/07/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060315293
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 10/26/2023 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049069975
Principal investigator 1 BioNTech SE $98.00 10/17/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060315333
Principal investigator 1 Merck Sharp & Dohme LLC $87,763.00 10/16/2023 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 1042542029
Principal investigator 1 Merck Sharp & Dohme LLC $6,250.00 10/11/2023 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 1042521507
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 10/06/2023 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049069943
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 10/06/2023 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049069953
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 10/06/2023 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049069963
Principal investigator 1 Janssen Research & Development, LLC $5,360.00 10/02/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156525
Principal investigator 1 Astellas Pharma Global Development $1,627.00 09/26/2023 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1022250209
Principal investigator 1 Astellas Pharma Global Development $3,322.00 09/15/2023 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1022250234
Principal investigator 1 Hoffmann-La Roche Limited $2,500.00 09/12/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
Fixed dose IV combination of atezo tira No dispute reported 06/30/2026 1040409765
Principal investigator 1 Hoffmann-La Roche Limited $18,000.00 09/12/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEBRASKA CANCER SPECIALISTS
Fixed dose IV combination of atezo tira No dispute reported 06/30/2026 1040409779
Principal investigator 1 BioNTech SE $1,149.20 09/01/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319497
Principal investigator 1 BioNTech SE $276.00 08/23/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060314993
Principal investigator 1 BioNTech SE $8,359.00 08/23/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060314999
Principal investigator 1 Astellas Pharma Global Development $2,250.00 08/16/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1022255671
Principal investigator 1 Novartis Pharmaceuticals Corporation $255.36 08/08/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY
An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) No dispute reported 06/30/2026 1017197913
Principal investigator 1 Janssen Research & Development, LLC $7,400.00 08/07/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156523
Principal investigator 1 BioNTech SE $2,298.40 08/01/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060315001
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 07/27/2023 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049070077
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 07/27/2023 Non-covered Recipient Entity
QUALITY CANCER CARE ALLIANCE
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049070087
Principal investigator 1 Janssen Research & Development, LLC $1,374.00 07/17/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156521
Principal investigator 1 Merck Sharp & Dohme LLC $2,250.00 07/17/2023 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 1042536311
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $878.41 07/05/2023 Non-covered Recipient Entity
Us Oncology Research Llc
Bay88-8223 Alpharadin Combo with abiraterone in CRPC No dispute reported 06/30/2026 1000204629
Principal investigator 1 BioNTech SE $750.00 07/04/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060314995
Principal investigator 1 BioNTech SE $1,500.00 07/04/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060314997
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065849
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065863
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065873
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065883
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065895
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065903
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065915
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065925
Principal investigator 1 Aveo Pharmaceuticals, Inc. $127.67 06/30/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049065935
Principal investigator 1 BioNTech SE $1,149.20 06/28/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060318137
Principal investigator 1 BioNTech SE $3,000.00 06/22/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060318139
Principal investigator 1 BioNTech SE $1,500.00 06/22/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060318145
Principal investigator 1 BioNTech SE $3,750.00 06/22/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319749
Principal investigator 1 BioNTech SE $1,000.00 06/22/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319751
Principal investigator 1 Janssen Research & Development, LLC $724.00 06/19/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 986156517
Principal investigator 1 Janssen Research & Development, LLC $256.00 06/19/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 986156519
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453569
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453575
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453583
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453589
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453595
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453603
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453609
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453615
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453621
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453627
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453631
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453637
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453643
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453649
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453655
Principal investigator 1 Eisai Inc. $520.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453663
Principal investigator 1 Eisai Inc. $35.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453669
Principal investigator 1 Eisai Inc. $35.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453675
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453681
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453687
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453693
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453699
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453705
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453711
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453717
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453723
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453729
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453735
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453741
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453747
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453754
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453761
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453767
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453773
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453779
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453785
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453791
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453797
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453803
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453809
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453815
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453821
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453827
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453833
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453841
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453847
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453853
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453859
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453865
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453871
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453877
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453883
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453889
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453895
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453901
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453907
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453913
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453919
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453925
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453931
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453937
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453943
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453949
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453955
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453961
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453967
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453973
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453979
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453985
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453991
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453997
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454003
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454009
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454015
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454021
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454027
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454035
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454041
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454047
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454053
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454059
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454065
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454071
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454077
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454083
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454089
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454095
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454101
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454107
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454113
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454119
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454125
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454131
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454137
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454143
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454147
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454153
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454159
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454165
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454171
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454177
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454183
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454189
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454195
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454201
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454205
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454211
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454217
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454223
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454229
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454235
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454241
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454247
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454253
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454259
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454263
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454269
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454277
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454283
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454289
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454295
Principal investigator 1 Eisai Inc. $200.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454303
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454309
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454315
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454323
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454329
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454335
Principal investigator 1 Eisai Inc. $15.00 06/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025454341
Principal investigator 1 BioNTech SE $1,160.00 06/08/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060318143
Principal investigator 1 BioNTech SE $276.00 06/08/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060318147
Principal investigator 1 Janssen Research & Development, LLC $200.00 06/05/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156515
Principal investigator 1 Astellas Pharma Global Development $3,322.00 06/02/2023 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1022250269
Principal investigator 1 BioNTech SE $2,298.40 05/30/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319753
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,603.80 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062961
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062971
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,489.75 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062985
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049062995
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,385.45 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049063004
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049063015
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,489.75 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049063026
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,603.80 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049063507
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049063517
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,385.45 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049063527
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,505.60 05/04/2023 Non-covered Recipient Entity
DANA-FARBER CANCER CARE NETWORK, INC.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1049063543
Principal investigator 1 BioNTech SE $14,398.00 05/03/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060318141
Principal investigator 1 BioNTech SE $1,149.20 05/03/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319747
Principal investigator 1 Janssen Research & Development, LLC $934.00 05/01/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156511
Principal investigator 1 Janssen Research & Development, LLC $7,400.00 05/01/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156513
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $105,791.50 04/24/2023 Non-covered Recipient Entity
Nebraska Cancer Specialists
Phase III 1L Melanoma non-inferiority rela+nivo FDC SubQ vs. rela+nivo FDC IV No dispute reported 06/30/2026 1027480797
Principal investigator 1 Janssen Research & Development, LLC $1,574.00 04/17/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156509
Principal investigator 1 Eisai Inc. $956.00 04/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453563
Principal investigator 1 BioNTech SE $3,447.60 04/04/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319745
Principal investigator 1 ABBVIE INC. $2,000.00 04/03/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEB
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998376227
Principal investigator 1 ABBVIE INC. $1,500.00 04/03/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEB
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998376229
Principal investigator 1 ABBVIE INC. $1,800.00 04/03/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEB
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998376231
Principal investigator 1 ABBVIE INC. $12,000.00 04/03/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC DBA NEB
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 998376233
Principal investigator 1 BioNTech SE $1,049.00 03/24/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319151
Principal investigator 1 BioNTech SE $7,586.00 03/24/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319153
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $57,312.00 03/16/2023 Non-covered Recipient Entity
Us Oncology Res Llc
Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) No dispute reported 06/30/2026 1027458197
Principal investigator 1 Exelixis Inc. $867.85 03/03/2023 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 1041938935
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,395.87 03/01/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1017235049
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 02/26/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025376919
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 02/26/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025376925
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $196.42 02/23/2023 Non-covered Recipient Entity
Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) No dispute reported 06/30/2026 1027451555
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,027.50 02/23/2023 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1027480987
Principal investigator 1 Astellas Pharma Global Development $6,644.00 02/22/2023 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1022250257
Principal investigator 1 BioNTech SE $196.00 02/22/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319149
Principal investigator 1 BioNTech SE $6,895.20 02/16/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Pre-commercial No dispute reported 06/30/2026 1060319147
Principal investigator 1 Janssen Research & Development, LLC $2,208.00 02/07/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156505
Principal investigator 1 Janssen Research & Development, LLC $1,374.00 02/07/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 986156507
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 02/02/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025376899
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 02/02/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025376905
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 02/02/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 1025376913
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42.00 01/26/2023 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialist
PhII 1L NSCLC Dose Safety, CoC Biomarker Evaluation - A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage No dispute reported 06/30/2026 1027480973
Principal investigator 1 Novartis Pharmaceuticals Corporation $149.40 01/26/2023 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1017220897
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,977.40 01/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, P.C.
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991127713
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $31,415.00 01/15/2023 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS) No dispute reported 06/30/2026 1027452483
Principal investigator 1 Eisai Inc. $956.00 01/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1025453557
Principal investigator 1 Novartis Pharmaceuticals Corporation $36.63 01/15/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY
A randomized double blind placebo controlled phase III study comparing the combination of PDR001 dabrafenib and trametinib versus placebo dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma No dispute reported 06/30/2026 1017198287
Principal investigator 1 Novartis Pharmaceuticals Corporation $834,244.61 01/11/2023 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1017199779
Principal investigator 1 Novartis Pharmaceuticals Corporation $645,032.43 01/05/2023 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1017233169
Principal investigator 1 Merck Sharp & Dohme LLC $1,062.00 01/04/2023 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 1042520161